Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Stoke Therapeutics is expected to release Q1 2026 results on May 7, 2026, with analysts projecting a loss of ($0.80) per share and revenue of about $6.48 million.
• In the prior quarter the company reported a ($0.97) EPS on $1.4M revenue, and analysts forecast roughly -$3 EPS for both the current and next fiscal years, signaling continued losses.
• Insiders sold a total of 69,699 shares (≈$2.53M) in the last 90 days (insiders own 9.5%), while the Street consensus is a Moderate Buy with an average price target of $41.83 and a market cap of $2.06B.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.80) per share and revenue of $6.4830 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.97) earnings per share (EPS) for the quarter. The business had revenue of $1.40 million during the quarter. Stoke Therapeutics had a negative return on equity of 2.05% and a negative net margin of 3.73%. On average, analysts expect Stoke Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Stoke Therapeutics Price Performance

Shares of STOK opened at $33.08 on Friday. The firm's 50 day moving average is $34.48 and its 200-day moving average is $32.08. The stock has a market capitalization of $2.06 billion, a P/E ratio of -275.64 and a beta of 1.20. Stoke Therapeutics has a 12-month low of $8.30 and a 12-month high of $40.22.

Insiders Place Their Bets

In other news, General Counsel Jonathan Allan sold 4,628 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $145,041.52. Following the transaction, the general counsel directly owned 28,836 shares of the company's stock, valued at $903,720.24. This trade represents a 13.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Arthur Tzianabos sold 4,355 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the completion of the transaction, the insider directly owned 31,339 shares in the company, valued at approximately $1,253,560. This trade represents a 12.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 69,699 shares of company stock valued at $2,526,714 over the last 90 days. 9.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its position in Stoke Therapeutics by 24.7% during the fourth quarter. Invesco Ltd. now owns 259,543 shares of the company's stock valued at $8,238,000 after purchasing an additional 51,468 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Stoke Therapeutics during the fourth quarter valued at approximately $330,000. Tudor Investment Corp ET AL purchased a new position in Stoke Therapeutics during the fourth quarter valued at approximately $613,000. Readystate Asset Management LP purchased a new position in Stoke Therapeutics during the fourth quarter valued at approximately $922,000. Finally, RTW Investments LP grew its position in Stoke Therapeutics by 8.3% during the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company's stock valued at $176,057,000 after purchasing an additional 423,331 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on STOK. Wolfe Research began coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They issued an "outperform" rating and a $40.00 price objective on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. Loop Capital set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Monday, January 5th. Wall Street Zen cut shares of Stoke Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. Finally, Wedbush lifted their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.